Skip to content
Buy This GLP
← Research
Safety

Compounded GLP-1 in FAERS: Reporting Odds for Errors and Contamination

A FAERS study found higher reporting odds for some events with compounded GLP-1 products. These reports cannot estimate patient risk.

Editorial profile: Carla MedinaBuy This GLP Editorial Team3 min read

FDA reports of dosing errors with compounded semaglutide describe specific incidents. This analysis compared the mix of reports for compounded and FDA-approved GLP-1 products in the FDA Adverse Event Reporting System (FAERS) [1].

What was reported

Of 81,078 GLP-1 reports from 2018 to 2024, 707 involved compounded products. The reporting odds ratio was 48.92 for preparation errors (95% CI 12.63 to 189.60) and 19.00 for contamination (95% CI 4.24 to 85.03) [1].

Hospitalization also had higher reporting odds (2.35). Administration and dosing errors had lower reporting odds in this analysis. Those categories can be reported differently across products.

How to read an FDA safety report

A reporting odds ratio compares the relative prominence of an event in submitted reports. The database lacks a reliable count of everyone treated. FDA cautions that the reports alone cannot establish causation or establish one product's safety relative to another [2].

FDA separately describes concerns including errors and inadequate temperature control in some shipped compounded products [3]. Contact the dispensing pharmacist or prescriber if the instructions or condition of a shipment raise questions.

Frequently asked

Does a reporting odds ratio measure the chance of harm?
It compares patterns among submitted reports. The number of people treated and their actual chance of harm cannot be derived from it.

Sources

  1. [1] McCall KL, et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Expert Opinion on Drug Safety. Source
  2. [2] U.S. Food and Drug Administration (2026). Understanding CDER’s Postmarket Safety Surveillance Programs and Public Data FDA. Source
  3. [3] U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA. Source

More in Safety